

UNITED STATES DESARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

	APPLICATION NO.	FILING DATE	FIRST NAMED IN	VENTOR		ATTORNEY DOCKET NO.
-	08/480.85	0 06/07/	95 PELLETY		F'	1414.657
Г	JAMIE L. J JONES AND	GREENE	HM21/0609	٦	LEE.	EXAMINER [)
	37TH FLOOL		T.		ART UNIT 1643	PAPER NUMBER
	ATLANTA G	A 30303			DATE MAIL ED.	. 06/09/98

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 08/480,850

Applicant(s)

Philip E. Pellett

Examiner

Danny Lee

Group Art Unit

		1045
X Responsive to communication(s) filed on Mar 27, 1998		
☐ Since this application is in condition for allowance except in accordance with the practice under Ex parte Quay\(\text{035}\)	for formal matters, prosecution of C.D. 11; 453 O.G. 213.	on as to the merits is closed
A shortened statutory period for response to this action is set longer, from the mailing date of this communication. Failure 1 application to become abandoned. (35 U.S.C. § 133). Extens 37 CFR 1.136(a).	to expire3 month(s),	
Disposition of Claim		
X Claim(s) <u>7, 8, and 16-21</u>		is/are pending in the applicat
Of the above, claim(s)	ic	/oro withdrawn farmer applicat
Claim(s)		rate withdrawn from consideration
		is/are allowed.
		is/are rejected.
☐ Claim(s)		is/are objected to.
Claims	are subject to i	restriction or election requirement.
Application Papers		
☐ See the attached Notice of Draftsperson's Patent Drawin	ng Review, PTO-948.	
The drawing(s) filed on is/are	objected to by the Examiner.	
☐ The proposed drawing correction, filed on	is 🗌 approved 🖂	lisapproved.
☐ The specification is objected to by the Examiner.		
The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. § 119		
Acknowledgement is made of a claim for foreign priority	under 35 U.S.C. § 119(a)-(d).	
☐ All ☐Some* None of the CERTIFIED copies o ☐ received.	f the priority documents have bee	n
received in Application No. (Series Code/Serial No.	ımber)	
received in this national stage application from the	International Bureau (PCT Rule	- · 17.2(a))
*Certified copies not received:		(4/).
 Acknowledgement is made of a claim for domestic priori 	y under 35 U.S.C. § 119(e).	
Attachment(s)		
☐ Notice of References Cited, PTO-892		
☐ Information Disclosure Statement(s), PTO-1449, Paper N	o(s)	
☐ Interview Summary, PTO-413		
☐ Notice of Draftsperson's Patent Drawing Review, PTO-94	8	
☐ Notice of Informal Patent Application, PTO-152		
SEE OFFICE ACTION ON	THE FOLLOWING PAGES	
		•

Art Unit: 1643

6 Mm 8 3

Examiner: Danny Lee Applicants: Pellet et al

The Group and/or Art Unit location of your application in the PTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to **Group Art Unit 1643 (formerly Art Unit 1815)**.

The Group and/or Art Unit FAX NUMBER has changed to 703-308-3014, 703-305-4242 as of July 7, 1997. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to *Group Art Unit 1643*.

Proposed correspondence for Examiner Lee should be faxed to the unofficial number (703-305-7401-unofficial).

- 1. Receipt is acknowledged of applicants' amendment in Paper No. 20, filed 3/27/98. Accordingly, claims 7-8, 16-21 are under consideration in the present application.
- 2. The rejection of claims 7-8, 16-21 under 35 U.S.C. § 103 as being unpatentable over Lee et al. (AA1) or Lee et al. (AW) in view of Luckow et al. (AO), Matsuura et al (AP) and further in view of Krishna et al (J. Gen. Virology, 1989) is maintained.

Applicant's arguments have been considered are not deemed persuasive. Applicant argues that the glycoprotein made by the AcDSMgG-1 is structurally different from Ac373'gG-1 is noted. The bands of the products of AcDSMgG-1 and Ac373'gG-1 are identified by human reactive sera and monoclonal antibodies. The monoclonal antibodies and human sera appears to react with both bands. Therefore the examiner is taking the position that the intensity differences

Serial Number: 08/480,850

Art Unit: 1643

Examiner: Danny Lee Applicants: Pellet et al

does not reflect a structural difference. Since the exact structure are not disclosed, one cannot assess patentable distinction between the proteins. From the gels of figure 2, both baculovirus expressed gG-1 proteins appear to be substantially the same. The reference does not disclose the amount of proteins loaded in the gel, the incubation time, the washing protocols, and other factors which could alter the western blot.

The Declaration of Dr. Pellett was considered but found unpersuasive.

In conclusion, the evidence do not establish a patentable distinction between the proteins. Luckow teaches that recombinant proteins produced in insect cells with baculovirus vectors are biologically active and for the most part appear to undergo post-translational processing (such as glycosylation) to produce recombinant products very similar to that of authentic proteins (page 51, column 2).

One of ordinary skill in the art at the time of applicant's invention would have been motivated to express the proteins in a baculovirus system since Luckow et al. and Matsuura et al. disclose the numerous advantages of baculovirus expressions systems, the importance of retaining an intact 5' nontranslated leader sequence of the polyhedron gene and one of ordinary skill would have had a reasonable expectation of success since Luckow et al. and Matsuura et al. both establish that the baculovirus system produces significant amounts of peptides and that such peptides "are in many cases, antigenically, immunologically, and functionally similar to their authentic counterparts." One of ordinary skill in the art at the time of applicant's invention would have a high expectation of success as taught by Krishna.

Serial Number: 08/480,850

Art Unit: 1643

ع والعامل

Examiner: Danny Lee Applicants: Pellet et al

No claims are allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire THREE MONTHS from the date of this action. In the event a first response is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than SIX MONTHS from the date of this final action.

Papers relating to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 located in Crystal Mall 1. The Fax number for Art Unit 1643 is (703) 305-3014. All Group 1600 Fax machines will be available to receive transmissions 24 hrs/day, 7 days/wk. Please note that the faxing of such papers must conform with the Notice published in the Official Gazette, 1096 OG 30, (November 15, 1989).

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to *Danny Lee* whose telephone number is (703) 305-7245. The Examiner can normally be reached on Monday-Friday from 8:00 AM-4:30 PM.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, *Marian Knode*, can be reached at (703) 308-4311.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Danny Lee
June 7, 1998
C:\STUFF\AMEND\08480850.6F

Marian C Knd MARIAN C. KNODE SUPERVISORY PATENT EXAMINER GROUP 1800/67